These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 15309383

  • 1. Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients.
    Okuno S, Inaba M, Kitatani K, Ishimura E, Yamakawa T, Nishizawa Y.
    Osteoporos Int; 2005 May; 16(5):501-9. PubMed ID: 15309383
    [Abstract] [Full Text] [Related]

  • 2. Significance of Bio-intact PTH(1-84) assay in hemodialysis patients.
    Inaba M, Okuno S, Imanishi Y, Ueda M, Yamakawa T, Ishimura E, Nishizawa Y.
    Osteoporos Int; 2005 May; 16(5):517-25. PubMed ID: 15322741
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure.
    Tsuchida T, Ishimura E, Miki T, Matsumoto N, Naka H, Jono S, Inaba M, Nishizawa Y.
    Osteoporos Int; 2005 Feb; 16(2):172-9. PubMed ID: 15164161
    [Abstract] [Full Text] [Related]

  • 7. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
    Ueda M, Inaba M, Okuno S, Maeno Y, Ishimura E, Yamakawa T, Nishizawa Y.
    Life Sci; 2005 Jul 22; 77(10):1130-9. PubMed ID: 15978265
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients.
    Reichel H, Roth HJ, Schmidt-Gayk H.
    Nephron Clin Pract; 2004 Jul 22; 98(4):c112-8. PubMed ID: 15627788
    [Abstract] [Full Text] [Related]

  • 9. Serum adiponectin and bone mineral density in male hemodialysis patients.
    Okuno S, Ishimura E, Norimine K, Tsuboniwa N, Kagitani S, Yamakawa K, Yamakawa T, Sato KK, Hayashi T, Shoji S, Nishizawa Y, Inaba M.
    Osteoporos Int; 2012 Jul 22; 23(7):2027-35. PubMed ID: 21927917
    [Abstract] [Full Text] [Related]

  • 10. Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients.
    Nakashima A, Yorioka N, Mizutani T, Yamagata Z, Ueno T, Takasugi N.
    Nephron Clin Pract; 2005 Jul 22; 99(3):c78-85. PubMed ID: 15665550
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Serum beta-type I collagen carboxyterminal telopeptide (beta-CTXs) and bone involvement in chronic renal failure].
    Oliveri B, Wittich AC, Nadal MA, Zeni SN.
    Medicina (B Aires); 2005 Jul 22; 65(4):321-8. PubMed ID: 16193710
    [Abstract] [Full Text] [Related]

  • 15. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK, Pietropolli A, Ticconi C, Gravotta E, De Martino MU, Fabbri A, Piccione E.
    J Obstet Gynaecol Res; 2009 Feb 22; 35(1):152-9. PubMed ID: 19215563
    [Abstract] [Full Text] [Related]

  • 16. [Skeletal scintigraph and some bone turnover markers in the diagnosis of renal osteodystrophy in hemodialysis patients].
    Bednarek-Skublewska A, Chrapko B, Ksiazek A.
    Pol Arch Med Wewn; 2003 Sep 22; 110(3):943-50. PubMed ID: 14699686
    [Abstract] [Full Text] [Related]

  • 17. Serum N-terminal midfragment vs. intact osteocalcin immunoradiometric assay as markers for bone turnover and bone loss in hemodialysis patients.
    Nagasue K, Inaba M, Okuno S, Kitatani K, Imanishi Y, Ishimura E, Miki T, Kim M, Nishizawa Y.
    Biomed Pharmacother; 2003 Mar 22; 57(2):98-104. PubMed ID: 12842495
    [Abstract] [Full Text] [Related]

  • 18. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
    Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriguchi A, Nishizawa Y.
    J Bone Miner Metab; 2004 Mar 22; 22(2):127-31. PubMed ID: 14999523
    [Abstract] [Full Text] [Related]

  • 19. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
    Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M.
    J Clin Endocrinol Metab; 2014 Nov 22; 99(11):4315-20. PubMed ID: 25093620
    [Abstract] [Full Text] [Related]

  • 20. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I, Balon BP, Rus I, Marc J.
    Nephrol Dial Transplant; 2005 Mar 22; 20(3):566-70. PubMed ID: 15665031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.